References
- Bar-Or A, Pachner A, Menguy-Vacheron F, et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 2014;74:659–674.
- Darrigade AS, Milpied B, Truchetet ME, et al. Pattern and severity of psoriasiform eruptions in patients with inflammatory bowel diseases, arthritis or skin inflammatory disorders treated with TNF-alpha inhibitors. Acta Derm Venereol. 2017;97:731–734.
- Verea MM, Del Pozo J, Yebra-Pimentel MT, et al. Psoriasiform eruption induced by infliximab. Ann Pharmacother. 2004;38:54–57.
- Teraki Y, Tanaka S, Hitomi K, et al. A case of generalized psoriasiform and pustular eruption induced by infliximab: evidence for skin-homing Th17 in the pathogenesis. Br J Dermatol. 2010;163:1347–1351.
- Mancinelli L, Amerio P, di Ioia M, et al. Nail loss after teriflunomide treatment: a new potential adverse event. Mult Scler Relat Disord. 2017;18:170–172.
- Rommer PS, Zettl UK. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients. Expert Opin Pharmacother. 2018;19:483–498.
- Guarnera C, Bramanti P, Mazzon E. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis. Drug Des Devel Ther. 2017;11:2193–2207.
- Liu CY, Tung TH, Lee CY, et al. Association of multiple sclerosis with psoriasis: a systematic review and meta-analysis of observational studies. Am J Clin Dermatol. 2018. DOI:10.1007/s40257-018-0399-9 [Epub ahead of print]
- Kepil Ozdemir S, Oner Erkekol F, Unal D, et al. Management of hypersensitivity reactions to proton pump inhibitors: a retrospective experience. Int Arch Allergy Immunol. 2016;171:54–60.